New drug ESG401 shows promise in early trial for advanced cancers

NCT ID NCT04892342

Completed Disease control Sponsor: Shanghai Escugen Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested an experimental drug called ESG401 in 156 people with advanced solid tumors (including breast, lung, and colorectal cancers) who had no other treatment options. The goal was to check the drug's safety, find the right dose, and see if it could shrink tumors. The trial is now complete, and results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ESG401 (an experimental drug given by IV infusion)
What this could lead to: If successful, this could point toward a new treatment option for several advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are expected and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASM OF STOMACH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm colorectal neoplasm gastric neoplasm lung neoplasm ovarian cancer urinary bladder neoplasm Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASM OF STOMACH NEOPLASMS, BLADDER NEOPLASMS, BREAST NEOPLASMS, COLORECTAL NEOPLASMS, LUNG NEOPLASMS, OVARIAN

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.